Results 301 to 310 of about 48,575 (332)

No increased pain among opioid‐dependent individuals treated with extended‐release naltrexone or buprenorphine‐naloxone: A 3‐month randomized study and 9‐month open‐treatment follow‐up study

American Journal on Addictions, 2019
BACKGROUND AND OBJECTIVES It is presently unclear whether extended-release naltrexone hydrochloride treatment induces pain or aggravates existing pain among individuals with opioid use disorders.
Zill-E-Huma Latif, K. Solli, Arild Opheim, N. Kunøe, J. Benth, P. Krajči, Kamni Sharma-Haase, L. Tanum   +7 more
semanticscholar   +1 more source

Comparison of two naltrexone treatment programs: naltrexone alone versus naltrexone plus behavior therapy.

NIDA research monograph, 1976
During a period of one year naltrexone was given to twenty-nine subjects. Fifteen of these subjects concurrently participated in a comprehensive behavior therapy program. The subjects in this naltrexone/behavior therapy group were maintanine on naltrexone for nearly twice as long as naltrexone group clients who received no therapy.
Michael Glazer, Beverly McCleave, Edward J. Callahan, Richard Arias, Richard A. Rawson   +4 more
openaire   +3 more sources

Naltrexone et tramadol

Toxicologie Analytique et Clinique, 2017
Objectif Rapporter un deces dans lequel l’association tramadol–naltrexone est peut-etre impliquee. Description du cas Un homme de 43 ans, alcoolo-dependant, subit une arthrodese de l’arriere du pied droit suite a un traumatisme des 2 chevilles 6 ans auparavant, a l’issue de laquelle il recoit une prescription de TOPALGIC® 100 (2/J) (J–10 avant le ...
François Paraf, Fanny Moreau, Jean-Michel Gaulier, C. Coeffeteau, L. Carton   +4 more
openaire   +2 more sources

Low Dose Naltrexone in the Treatment of Fibromyalgia.

Current Rheumatology Reviews, 2018
BACKGROUND ConclusionFibromyalgia is a chronic pain disorder characterized by diffuse musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment.
S. Metyas, Christina Chen, K. Yeter, J. Solyman, D. Arkfeld   +4 more
semanticscholar   +1 more source

Assessment of naltrexone in the treatment of schizophrenia

Psychopharmacology, 1981
Naltrexone, a long acting opiate antagonist, and placebo were administered to eight schizophrenics in doses of 200 mg per day for 1 week in a double-blind, crossover design. No improvement was noted, and no side effects resembling the opiate withdrawal syndrome with naltrexone were found. Naltrexone does not appear to alter schizophrenic symptomatology.
Michael Rosenblatt, Robert H. Gerner, Michael J. Gitlin   +2 more
openaire   +3 more sources

Naltrexone for the treatment of comorbid tobacco and pornography addiction.

American Journal on Addictions, 2017
BACKGROUND AND OBJECTIVES Co-occurring addictive disorders are common, however treatment strategies for this population have not been extensively studied. This is especially the case for behavioral addictions.
Noah A. Capurso
semanticscholar   +1 more source

Erectile Function and Naltrexone

Annals of Internal Medicine, 1986
Excerpt To the editor: The male patient with erectile dysfunction who has had normal findings on urologic, endocrinologic, and hemodynamic evaluations is usually referred for sexual counseling with...
openaire   +2 more sources

Naltrexone and Dysphoria: Fact or Myth?

The American Journal on Addictions, 2002
Naltrexone is an opiate antagonist used as a pharmacologic adjuvant for the treatment of opiate and alcohol addiction. It has been hypothesized that naltrexone blocks the stress‐response and well‐being effects associated with opioid peptides. This raises the clinical concern that naltrexone may cause dysphoria.
Michael McCann, Karen Miotto, B A Janice Basch, Walter Ling, Richard A. Rawson   +4 more
openaire   +3 more sources

Use of naltrexone in ketamine dependence

Addictive Behaviors, 2014
Ketamine is used as a cheap alternative to anaesthetic agents in developing countries. It is also misused as a rave drug because of its psychedelic effect. There are no guidelines for effective management of ketamine withdrawal effects or dependence.
Amit Garg, Pallavi Sinha, Pankaj Kumar, Om Prakash   +3 more
openaire   +2 more sources

▼Naltrexone/bupropion for obesity

Drug and Therapeutics Bulletin, 2017
▼ Naltrexone/bupropion (Mysimba - Orexigen Therapeutics Ireland Limited) is a fixed-dose combination product for the treatment of adults who are obese or overweight with at least one weight-related comorbidity, as an adjunct to diet and lifestyle modifications.
openaire   +2 more sources